Journals / MN Oftalmoloji / 2000 / Cilt: 7 - Sayı: 4

Results of chemoreduction treatment in unilateral retinoblastoma

Tek taraflı retinoblastomda kemoredüksiyon tedavisi sonuçları

Pages
316–320
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

DISCUSSION: Our results indicate that in unilateral retinoblastoma, stage II-III eyes respond well to chemoreduction and sequential treatment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:PURPOSE: To report the results of chemoreduction and sequential treatment methods in unilateral retinoblastoma.
📊
Key Findings & Data:MATERIAL AND METHOD: Unilateral retinoblastoma cases underwent 6 cycle chemoreduction consisting of vincristine, etoposide and carboplatin.
💡
Conclusion & Impact:DISCUSSION: Our results indicate that in unilateral retinoblastoma, stage II-III eyes respond well to chemoreduction and sequential treatment.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Hipertermi · indüklenmiş · Radyoterapi

Abstract

PURPOSE: To report the results of chemoreduction and sequential treatment methods in unilateral retinoblastoma. MATERIAL AND METHOD: Unilateral retinoblastoma cases underwent 6 cycle chemoreduction consisting of vincristine, etoposide and carboplatin. Sequential treatment methods (cryotherapy, transpupillary thermotherapy, Ru-106 plaque radiotherapy and external beam irradiation) were applied after the second chemoreduction course as required. Eyes which were unresponsive to treatment or which demonstrated recurrence were subjected to enucleation. RESULTS: 22 eyes of 22 consecutive patients with unilateral retinoblastoma were included in our study. At a mean folfow-up of 14.1 (4-28) months, a total of 16 eyes underwent enucleation after chemoreduction and sequential treatment. The mean age of the enucleation group was 2.6 years versus 1.1 years in the eye conservation group. The difference in the 2 groups with respect to agewas significant (Mann-Whithney U testi, p=0.02). The mean interval from the initial examination to enucleation was 9.3 (2-28) months. Three of 4 Reese-Ellsworth stage II-III eyes, 1 of 4 stage IV eyes, 1 of 5 stage Va eyes and 1 of 9 stage Vb eyes were salvaged using chemoreduction and sequential treatment There was a statistical significance between stage II-III and stage IV-V eyes with respect to globe salvage (Fisher's exact test, p=0.04). DISCUSSION: Our results indicate that in unilateral retinoblastoma, stage II-III eyes respond well to chemoreduction and sequential treatment. However, stage IV and Va-b eyes generally do not respond well. However, each case must be individualized and occasional stage IV and Va-b cases do respond to chemoreduction and sequential treatment. Early age at diagnosis may improve the chance of globe salvage using chemoreduction and sequential treatment.

Özet

AMAÇ: Tek taraflı retinoblastomda kemoredüksiyon tedavisi sonuçlarını incelemek. GEREÇ VE YÖNTEM: Tek taraflı retinoblastom olgularında vinkristin, etoposid ve karboplatinden oluşan 6 kür kemoredüksiyon tedavisi uygulanmıştır. 2. kür kemoredüksiyondan sonra ek tedavi yöntemleri (kriyoterapi, transpupiller termoterapi, Ru-106 plak radyoterapisi, dışsal ışın tedavisi) yapılmıştır. Tedaviye cevap vermeyen veya nükseden gözlere enükleasyon ameliyatı uygulanmıştır. SONUÇLAR: Çalışmamıza Ekim 1998-Ekim 2000 tarihleri arasında 22 tek taraflı olgunun 22 gözü dahil edilmiştir. Ortalama 14.1 (4-28) ay izlem süresinde toplam 16 göze enükleasyon uygulanmıştır. Enükleasyon uygulanan olguların ortalama yaşı 2.6 iken, gözü korunan olguların ortalama yaşı 1.1'dir. İki grup arasındaki fark anlamlıdır (Mantı-Whithney U testi, p=0.02). Olgunun ilk muayenesinden enükleasyona kadar geçen süre ortalama 9.3 (2-28) aydır. 4 Reese-Ellsworth evre II-III gözün 3'ü, 4 evre IV gözün 1'i, 5 evre Va gözün 1'i ve 9 evre Vb gözün 1'i kemoredüksiyon ve ek tedaviler sonucunda korunmuştur. Çalışma sonuçlarımıza göre evre II-III olgularla evre IV-V olgular arasında göz korunması yönünden anlamlı bir fark vardır (Fisher's exact testi, p=0.04).

🔖

Cite This Article

GÜNDÜZ, K. (2000). Results of chemoreduction treatment in unilateral retinoblastoma. MN Oftalmoloji, Cilt: 7 - Sayı: 4, 316–320. https://ajindex.com/articles/296474

References (17)

  1. Elisworth RM. The practical management of retinoblastoma. Trans Am Ophthalmol Soc 1969;67:463-534
  2. Shields JA, Shields CL Intraocular Tumors: A Text and Atlas. Philadelphia, PA: WB Saunders, 1992: 305-91
  3. Shields CL, Shields JA. Review. Recent developments in the management of rellnoblastama. J Ped Ophthalmol Strabismus 1999;36:8-18
  4. White L Chemotherapy far retinoblastoma: where do we go from here? Ophthalmic Pedialric Genet 1991;12:115-30
  5. Goble RR, McKenzie J, Kingston JE, Plowman PN, Hungerford JL Orbital recurrence of retinoblasloma successfully treated by combined therapy. Br J Ophthalmol 1990;74:97-8
  6. Pratt CB, Fonlanesi J, Chenaille P, et al. Chemotherapy lor extraocular retinoblastoma. Pediatrin Hematology and Oncology 1994;11:301-9
  7. Doz F, Khelfaaui F, Mosseri V, et al. The role of chemotherapy in orbital involvement of retinoblastoma. The experience of a single institution with 33 patlents. Cancer 1994;74:722-32
  8. O'Brien JM, Smilh BJ. Chemotherapy in the treatment of retinoblastoma. Ini Ophthalmol Clin 1996;36:11-24
  9. Gallie BL, Bunding A, DeBoer G, et ai. Chemotherapy with focal therapy can cure intraocular retinablastoma without radiotherapy. Arch Ophthalmol 1996;114:1321-B
  10. Shields CL, De Potter P, Himmelstein B, Shields JA, Meadows A, Maris J. ehemoreduetion in the initial management of intraocular retinablastoma. Arch Ophthaimol 1996:114:1330-8
  11. Kingstan JE, Hungerford JL, Madreperla SA, Plowman PN. Results af combined chemotherapy and radiatherapy for advanced intraocular retinablastoma. Arch Ophthalmol 1996:114:1339-43
  12. Murphree AL, Villablanca JG, Deegan WF, et al. Chemotherapy plus local treatment İn the management of intraocular refinoblastoma. Arch Ophthalmol 1996:114:1348-56
  13. Greenwald MJ, Strauss LC. Trealment of intraocular retinoblastoma with carboplatin and etoposide chemotherapy. Ophthalmology 1996;103:1989-97
  14. Singh AD, Garway-Heath D, Love S, et al. Relationship of regression pattern to regression in retinoblastoma. Br J Ophthalmol 1993;77:12-16
  15. Bechrakis NE, Bomfeld N, Schueler A, Coupland SE, Henze G, Foersler MH. Clinicopathologic features af retinoblastoma after primary ehemoreduetion. Arch Ophthalmol 1998;116:887-893
  16. Dithmar S, Aabert TM Jr, Grossniklaus HE. Histopathologic changes in retinoblastoma after ehemareduetion. Retina 2000;20:33-36
  17. Abramson DH, Frank CM. Second nonocular tumars İn survivars of bilateral retinoblaslama. A possible age effect on radiatio